DE3852118T2 - Protease-ähnliche zytotoxische lymphozyten-spezifische moleküle und verfahren. - Google Patents

Protease-ähnliche zytotoxische lymphozyten-spezifische moleküle und verfahren.

Info

Publication number
DE3852118T2
DE3852118T2 DE3852118T DE3852118T DE3852118T2 DE 3852118 T2 DE3852118 T2 DE 3852118T2 DE 3852118 T DE3852118 T DE 3852118T DE 3852118 T DE3852118 T DE 3852118T DE 3852118 T2 DE3852118 T2 DE 3852118T2
Authority
DE
Germany
Prior art keywords
protease
specific molecules
cytotoxic lymphocyte
cytotoxic
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3852118T
Other languages
English (en)
Other versions
DE3852118D1 (de
Inventor
Robert Bleackley
Corrine Lobe
Verner Paetkau
Michael James
Michael Murphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seragen Inc
Original Assignee
Seragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seragen Inc filed Critical Seragen Inc
Publication of DE3852118D1 publication Critical patent/DE3852118D1/de
Application granted granted Critical
Publication of DE3852118T2 publication Critical patent/DE3852118T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6467Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/142Toxicological screening, e.g. expression profiles which identify toxicity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE3852118T 1987-01-13 1988-01-13 Protease-ähnliche zytotoxische lymphozyten-spezifische moleküle und verfahren. Expired - Fee Related DE3852118T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US296087A 1987-01-13 1987-01-13
PCT/US1988/000071 WO1988005471A1 (en) 1987-01-13 1988-01-13 Cytotoxic lymphocyte-specific protease-related molecules and methods

Publications (2)

Publication Number Publication Date
DE3852118D1 DE3852118D1 (de) 1994-12-22
DE3852118T2 true DE3852118T2 (de) 1995-06-29

Family

ID=21703390

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3852118T Expired - Fee Related DE3852118T2 (de) 1987-01-13 1988-01-13 Protease-ähnliche zytotoxische lymphozyten-spezifische moleküle und verfahren.

Country Status (5)

Country Link
EP (1) EP0300033B1 (de)
JP (1) JPH01502198A (de)
AT (1) ATE114159T1 (de)
DE (1) DE3852118T2 (de)
WO (1) WO1988005471A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004692A (en) * 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
CA2074081A1 (en) * 1990-01-19 1991-07-20 Robert C. Bleackley Cytotoxic cell-specific protease-related molecules and methods

Also Published As

Publication number Publication date
EP0300033B1 (de) 1994-11-17
JPH01502198A (ja) 1989-08-03
EP0300033A4 (de) 1990-02-05
DE3852118D1 (de) 1994-12-22
EP0300033A1 (de) 1989-01-25
WO1988005471A1 (en) 1988-07-28
ATE114159T1 (de) 1994-12-15

Similar Documents

Publication Publication Date Title
DK552684A (da) Desulfatohirudiner samt deres fremstilling og anvendelse
SE8206168D0 (sv) Preparations and process for preparation thereof
ES2062355T3 (es) Composicion farmaceutica que comprende loratadina, ibuprofeno y pseudoefedrina.
ATE314116T1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
NO885109D0 (no) FremgangsmŸte og middel for Ÿ forhindre blodpropp.
FI862756A0 (fi) Fibroektiner.
DK66692A (da) En mammal cytokin, il-11
ATE126535T1 (de) ''walk-through''-mutagenese.
DE3684078D1 (de) Reinigung und aktivierung von proteinen aus unloeslichen einschlusskoerpern.
ES2032755T3 (es) Medicamentos conteniendo hexadecil-fosfocolina con efecto antitumoral.
FI946004A (fi) Lääketieteellisessä toimenpiteessä käytettävä trombiiniverifraktio
DE69131589T2 (de) Ribosomen-inaktivierende Proteine, inaktive Vorläuferformen derselben, Verfahren zur Herstellung und eine Methode zur Nutzung
DK0502872T3 (da) Fremgangsmåder og materialer til eksprimering af human plasminogenvariant
DE69110713D1 (de) 7-Oxabicycloheptan-imidazol-prostaglandin-Analoge, verwendbar bei der Behandlung von thrombotischen und vasospastischen Erkrankungen.
EP0336779A3 (de) Durch kovalenten Ersatz von Wasserstoffbrücken stabilisierte Polypeptide
IT998023B (it) Procedimento per ridurre l4ossigeno biochimico necessario per le acque di scarico e per il ricupero delle proteine in esse contenute
AR004093A1 (es) El uso de una proteina derivada de una quimioquina de mamifero y un medicamento util para movilizar celulas tronco hematopoyeticas.
DE3852118T2 (de) Protease-ähnliche zytotoxische lymphozyten-spezifische moleküle und verfahren.
ATE49420T1 (de) Verfahren zur reinigung von plasminogenaktivatoren (pa).
FI885025A0 (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
PT83721B (pt) Processo de preparacao de composicoes farmaceuticas a base de activadores de plasminogenio com actividade trombolitica
DE59107762D1 (de) Komplexe, enthaltend S(+)-Phenyl-alkansäuren und alpha-Hydroxy-alkansäuren
NO920524D0 (no) Kynurensyrederivater, deres fremstilling og farmasoeytiskeblandinger inneholdende disse
ATE75938T1 (de) Enantiomere des propafenons enthaltende therapeutische mittel.
IT7819048A0 (it) Procedimento ed impianto per la concentrazione di acque con elevato contenuto di sale e povere in sostanze volatili, in particolare di acque di rifiuto delle industrie.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee